Teleflex 過去の業績

過去基準チェック /16

Teleflexの収益は年間平均-7.9%の割合で減少していますが、 Medical Equipment業界の収益は年間減少しています。収益は年間1.1% 3.9%割合で増加しています。 Teleflexの自己資本利益率は5.3%であり、純利益率は7.9%です。

主要情報

-7.9%

収益成長率

-8.3%

EPS成長率

Medical Equipment 業界の成長	4.3%
収益成長率	3.9%
株主資本利益率	5.3%
ネット・マージン	7.9%
前回の決算情報	29 Sep 2024

Recent updates

収支内訳

Teleflex の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

DB:TBH 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
29 Sep 24	3,026	238	1,163	153
30 Jun 24	3,008	265	1,154	152
31 Mar 24	3,001	296	1,141	150
31 Dec 23	2,974	358	991	154
01 Oct 23	2,959	405	925	161
02 Jul 23	2,899	369	904	161
02 Apr 23	2,860	363	888	159
31 Dec 22	2,791	363	861	154
25 Sep 22	2,795	412	862	147
26 Jun 22	2,808	510	856	141
27 Mar 22	2,817	488	859	137
31 Dec 21	2,810	485	852	131
26 Sep 21	2,759	434	836	129
27 Jun 21	2,687	351	829	126
28 Mar 21	2,540	280	784	122
31 Dec 20	2,537	336	782	120
27 Sep 20	2,507	367	772	117
28 Jun 20	2,527	479	770	116
29 Mar 20	2,612	551	798	114
31 Dec 19	2,595	462	798	114
29 Sep 19	2,556	442	804	111
30 Jun 19	2,517	269	812	109
31 Mar 19	2,475	183	814	107
31 Dec 18	2,448	196	744	106
30 Sep 18	2,402	66	822	104
01 Jul 18	2,327	89	784	99
01 Apr 18	2,246	170	738	93
31 Dec 17	2,146	155	696	85
01 Oct 17	2,065	259	634	75
02 Jul 17	1,986	246	611	69
02 Apr 17	1,931	227	594	64
31 Dec 16	1,868	237	570	59
25 Sep 16	1,828	267	569	56
26 Jun 16	1,816	262	569	54
27 Mar 16	1,795	248	568	52
31 Dec 15	1,799	236	574	52
27 Sep 15	1,798	197	578	56
28 Jun 15	1,808	191	577	58
29 Mar 15	1,821	194	586	60
31 Dec 14	1,827	190	586	61
28 Sep 14	1,802	174	573	62
29 Jun 14	1,759	164	554	62
30 Mar 14	1,711	159	526	64
31 Dec 13	1,685	151	502	65

質の高い収益: TBHは高品質の収益を持っています。

利益率の向上: TBHの現在の純利益率 (7.9%)は、昨年(13.7%)よりも低くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: TBHの収益は過去 5 年間で年間7.9%減少しました。

成長の加速: TBHは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: TBHは過去 1 年間で収益成長率がマイナス ( -41% ) となったため、 Medical Equipment業界平均 ( 10.1% ) と比較することが困難です。

株主資本利益率

高いROE: TBHの自己資本利益率 ( 5.3% ) は低いとみなされます。

Teleflex 過去の業績

過去 基準チェック /16

主要情報

最近の業績更新

Third quarter 2024 earnings released: EPS: US$2.37 (vs US$2.93 in 3Q 2023)

Second quarter 2024 earnings released: EPS: US$1.70 (vs US$2.37 in 2Q 2023)

First quarter 2024 earnings released: EPS: US$0.33 (vs US$1.65 in 1Q 2023)

Full year 2023 earnings released: EPS: US$7.61 (vs US$7.74 in FY 2022)

Third quarter 2023 earnings released: EPS: US$2.93 (vs US$2.17 in 3Q 2022)

Second quarter 2023 earnings released: EPS: US$2.37 (vs US$2.25 in 2Q 2022)

Recent updates

Third quarter dividend of US$0.34 announced

Teleflex Incorporated Revises Earnings Guidance for the Year 2024

Third quarter 2024 earnings released: EPS: US$2.37 (vs US$2.93 in 3Q 2023)

Teleflex Incorporated Announces Quarterly Dividend, Payable December 16, 2024

Teleflex Incorporated Announces First Patient Enrolled Barrigel™ Rectal Spacer Trial for Post Radical Prostatectomy Radiation Therapy

Teleflex Incorporated Launches Next-Generation Arrow VPS Rhythm DLX Device and NaviCurve Stylet in Canada

Teleflex Incorporated Announces the Presentation of Data Supporting the Safety and Efficacy of Barrigel Rectal Spacer

Second quarter dividend of US$0.34 announced

Second quarter 2024 earnings released: EPS: US$1.70 (vs US$2.37 in 2Q 2023)

Teleflex Incorporated (NYSE:TFX) announces an Equity Buyback for $500 million worth of its shares.

Teleflex Incorporated Revises Earnings Guidance for the Full Year 2024

Teleflex Incorporated Expands Intraosseous Vascular Access Portfolio with New Arrow™ EZ-IO™ Intraosseous Access Procedure Tray

First quarter dividend of US$0.34 announced

Teleflex Incorporated Announces Quarterly Cash Dividend, Payable on June 14, 2024

Teleflex Incorporated Raises Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$0.33 (vs US$1.65 in 1Q 2023)

Teleflex Incorporated, Annual General Meeting, May 03, 2024

Fourth quarter dividend of US$0.34 announced

Full year 2023 earnings released: EPS: US$7.61 (vs US$7.74 in FY 2022)

Teleflex Incorporated Announces Quarterly Dividend, Payable on March 15, 2024

Teleflex Incorporated Offers Its Titan SGS Stapler with Staple Line Reinforcement

Teleflex Incorporated Announces First Patient Enrollment in ACCESS-MANTA Registry

Teleflex Incorporated Announces A New Peer-Reviewed Study in the Nature Journal Prostate Cancer and Prostatic Diseases Confirms the Position of the UroLift System as the Gold Standard in Minimally Invasive Surgical Treatment

Teleflex Incorporated Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$2.93 (vs US$2.17 in 3Q 2022)

Teleflex Incorporated (NYSE:TFX) acquired Palette Life Sciences for $650 million.

Teleflex Incorporated (NYSE:TFX) acquired Palette Life Sciences for $650 million.

Teleflex Incorporated Announces Extension of Arrow ErgoPack Complete System to Hemodialysis and Large Bore Central Venous Catheters

Upcoming dividend of US$0.34 per share at 0.6% yield

Teleflex Incorporated Updates Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$2.37 (vs US$2.25 in 2Q 2022)

Teleflex Incorporated Receives FDA Clearance for Expanded Indication for QuikClot Control+(TM) Hemostatic Device Usage in Cardiac Surgical Procedures

Teleflex Incorporated (NYSE:TFX) entered into a definitive agreement to acquire Palette Life Sciences AB for $650 million.

Teleflex Incorporated (NYSE:TFX) entered into a definitive agreement to acquire Palette Life Sciences AB from Östersjöstiftelsen, Endowment Arm, Praktikerinvest AB and Recipharm Venture Fund AB for $650 million.

Teleflex Incorporated Receives FDA Clearance for the Wattson Temporary Pacing Guidewire

Teleflex Incorporated Announces the Arrow(R) EZ-Io(R) Needle Is Now FDA Cleared for Use in an MRI Environment

Teleflex Announces Quarterly Dividend, June 15, 2023

Teleflex Incorporated Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings released: EPS: US$1.65 (vs US$1.65 in 1Q 2022)

Full year 2022 earnings released: EPS: US$7.74 (vs US$10.37 in FY 2021)

Insufficient new directors

Upcoming dividend of US$0.34 per share

Teleflex Incorporated Announces Worldwide Recall of Affected Lots of Gibeck Iso-Gard Filter Products

Third quarter 2022 earnings released: EPS: US$2.17 (vs US$4.26 in 3Q 2021)

Teleflex Incorporated Revises Earnings Guidance for the Year 2022

Teleflex Incorporated (NYSE:TFX) completed the acquisition of Standard Bariatrics, Inc.

Teleflex Incorporated Launches New Arrow® Pressure Injectable Midline Catheter Portfolio

Teleflex Incorporated (NYSE:TFX) entered into a definitive agreement to acquire Standard Bariatrics, Inc. for $300 million.

Upcoming dividend of US$0.34 per share

Second quarter 2022 earnings released: EPS: US$2.25 (vs US$1.78 in 2Q 2021)

Teleflex Incorporated Provides Earnings Guidance for the Full Year of 2022

Teleflex Incorporated (NYSE:TFX) acquired unknown stake in Traverse Vascular Inc.

Teleflex Incorporated Announces First Patient Enrollment in MANTA Ultra Study

Teleflex Launches New Arrow Pressure Injectable Midline Catheter in Australia and New Zealand

Teleflex Incorporated Launches New Arrow Pressure Injectable Midline Catheter in Europe, the Middle East and Africa Region

Teleflex Incorporated Reaffirms Earnings Guidance for the Full Year of 2022

Teleflex Incorporated Announces Regulatory Clearance for Its Urolift® System in China for the Treatment of Benign Prostatic Hyperplasia

Teleflex Announces Health Canada Approval of MANTA® Vascular Closure Device

Teleflex Incorporated Declares Quarterly Cash Dividend, Payable on June 15, 2022

First quarter 2022 earnings released: EPS: US$1.65 (vs US$1.60 in 1Q 2021)

Insufficient new directors

Teleflex Announces the Launch of the UroLift® System in Japan for the Treatment of Benign Prostatic Hyperplasia

Teleflex Incorporated, Annual General Meeting, Apr 29, 2022

Teleflex Incorporated Announces Board Changes

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Teleflex Incorporated Declares Quarterly Cash Dividend, Payable March 15, 2022

Teleflex Receives FDA Clearance for Expanded Indication for Specialty Catheter and Coronary Guidewire Use in CTO PCI Procedures

Insufficient new directors

Independent Director recently bought €273k worth of stock

過去基準チェック /16